Table 1. Summary of marketing authorizations per LA country according to the availability of OS data and risk of bias assessment of the cancer drugs approved by EMA between 2009–2016.
| LA countries | Drugs included in the Survival list (n = 28) | Drugs included in the Bias list (n = 27) | ||
|---|---|---|---|---|
| No OS (n = 17)[100%] | OS reported (n = 11)[100%] | No trial or no trial at low risk of bias (n = 13)[100%] | At least one trial at low risk of bias (n = 14)[100%] | |
| Argentina | 15 [88.2] | 10 [90.9] | 10 [76.9] | 11 [78.6] |
| Brazil | 13 [76.5] | 11 [100] | 11 [84.6] | 11 [78.6] |
| Chile | 12 [70.6] | 9 [81.8] | 10 [76.9] | 8 [57.1] |
| Colombia | 12 [70.6] | 8 [72.7] | 9 [69.2] | 6 [42.9] |
| Ecuador | 12 [70.6] | 9 [81.8] | 9 [69.2] | 6 [42.9] |
| Panama | 8 [47.1] | 5 [45.4] | 8 [61.8] | 6 [42.9] |
| Peru | 12 [70.6] | 11 [100] | 10 [76.9] | 7 [50.0] |